Simon Khagi
University of North Carolina at Chapel Hill
23 Papers
22 Citations
Simon Khagi is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 16 publications.
Chat about Author
Papers
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M. Liau,Keyoumars Ashkan,David Tran,Jian Campian,John E. Trusheim,Charles S. Cobbs,Jason Heth,Michael Salacz,Sarah A. Taylor,Stacy D. D’Andre,Fabio M. Iwamoto,Edward J. Dropcho,Yaron A. Moshel,Kevin A. Walter,Clement Pillainayagam,Robert Aiken,Rekha Chaudhary,Samuel Goldlust,Daniela A. Bota,Paul Duic,Jai Grewal,Heinrich Elinzano,Steven A. Toms,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Steven Brem,Matthew G. Ewend,Simon Khagi,Jana Portnow,Lyndon Kim,William G. Loudon,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Scott Lindhorst,Jose Lutzky,Andrew E. Sloan,Gabriele Schackert,Dietmar Krex,Hans-Jorg Meisel,Julian Wu,Raphael P. Davis,Christopher Duma,Arnold B. Etame,David Mathieu,Santosh Kesari,David Piccioni,Manfred Westphal,David S. Baskin,Pamela Z. New,Michel Lacroix,Sven-Axel May,Timothy J. Pluard,Victor Tse,Richard M. Green,John L. Villano,Michael Pearlman,Kevin Petrecca,Michael Schulder,Lynne Taylor,Anthony E. Maida,Robert M. Prins,Timothy F. Cloughesy,Paul Mulholland,Marnix L. Bosch +68 more
TL;DR: Addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival, and overall adverse events withDCVax were comparable to standard Therapy alone.
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Linda M. Liau,Keyoumars Ashkan,Steven Brem,Jian Campian,John E. Trusheim,Fabio M. Iwamoto,David Tran,George Ansstas,Charles Cobbs,Jason Heth,Michael Salacz,Stacy D. D’Andre,Robert Aiken,Yaron A. Moshel,Joo Yeon Nam,Clement Pillainayagam,Stephanie Ann Wagner,Kevin A. Walter,Rekha Chaudhary,Samuel Goldlust,Ian Lee,Daniela A. Bota,Heinrich Elinzano,Jai Grewal,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Matthew G. Ewend,Simon Khagi,D Lovick,Jana Portnow,Lyndon Kim,William G Loudon,Nina L. Martinez,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Pierre Giglio,Oleg Gligich,Dietmar Krex,Scott Lindhorst,Jose Lutzky,Hans Joerg Meisel,Minou Nadji-Ohl,L. Sanchin,Andrew E. Sloan,Lynne P. Taylor,Julian K. Wu,Erin M. Dunbar,Arnold B. Etame,Santosh Kesari,David Mathieu,David Piccioni,David S. Baskin,Michel Lacroix,Sven-Axel May,Pamela New,Timothy J. Pluard,Steven A. Toms,Victor Tse,Scott Peak,John L. Villano,James Battiste,Paul Mulholland,Michael Pearlman,Kevin Petrecca,Michael Schulder,Robert M. Prins,Alton L. Boynton,Marnix L. Bosch +72 more
TL;DR: In this article , treatment with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) was associated with improved overall survival (OS) for patients with newly diagnosed glioblastoma (nGBM) and recurrent gliomatosis (rGBM), compared with standard of care (SOC).
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Farshad Nassiri,Vikas Patil,Leeor S. Yefet,Olivia Singh,Jeff C. Liu,Takafumi N. Yamaguchi,Mariza Daras,Timothy F. Cloughesy,Howard Colman,Priya Kumthekar,Clark C. Chen,Robert Aiken,Morris D. Groves,Shirley Ong,Rohan Ramakrishna,Michael A. Vogelbaum,Simon Khagi,Thomas J. Lawley,Jason M. Melear,David M. Peereboom,Analiz Rodriguez,Maxim Yankelevich,Suresh G. Nair Md,Vinay K. Puduvalli,Kenneth Aldape,Andrew F. Gao,Alvaro López-Janeiro,Carlos E. de Andrea,Marta M. Alonso,P. Boutros,Joan M. Robbins,Warren P. Mason,Adam M. Sonabend,Roger Stupp,Juan Fueyo,Candelaria Gomez-Manzano,Frederick F. Lang,Gelareh Zadeh +37 more
TL;DR: In this article , the authors evaluated the combination of intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous anti-PD-1 antibody pembrolizumab in recurrent glioblastoma.
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.
Stephen J Bagley,Shawn Kothari,Rifaquat Rahman,Eudocia Q. Lee,Gavin P. Dunn,Evanthia Galanis,Susan M. Chang,Louis B. Nabors,Manmeet S Ahluwalia,Roger Stupp,Minesh P. Mehta,David A. Reardon,Stuart A. Grossman,Erik P. Sulman,John Sampson,Simon Khagi,Michael Weller,Timothy F. Cloughesy,Patrick Y. Wen,Mustafa Khasraw +19 more
TL;DR: In this paper, the authors provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as "recruitment" or "not-yet-recruiting" as of February, 2021.
110
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Aaron Tan,Stephen J Bagley,Patrick Y. Wen,Michael Lim,Michael Platten,Michael Platten,Howard Colman,David M. Ashley,Wolfgang Wick,Susan M. Chang,Evanthia Galanis,Alireza Mansouri,Simon Khagi,Minesh P. Mehta,Amy B. Heimberger,Vinay K. Puduvalli,David A. Reardon,Solmaz Sahebjam,John Simes,Scott J. Antonia,Donald A. Berry,Mustafa Khasraw +21 more
TL;DR: In this paper, a MEDLINE search was conducted using a modified Cochrane Highly Sensitive Search Strategy for published clinical trials between July 1, 2017, and June 30, 2020, in the top-ranked medical and oncology journals.
60